Response: More about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors

Blood

Volumn 112, Issue 1, 2008, Pages 209-210

  Bonig, Halvard ^a   Wundes, Annette ^a   Papayannopoulou, Thalia ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; NATALIZUMAB;

ALLERGIC ENCEPHALOMYELITIS; DISEASE ACTIVITY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; LETTER; LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 61849099475     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-151340     Document Type: Letter

References (4)

1. Bonig H, Wundes A, Chang KH. Lucas S, Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008;111:3439-3441.
2. Khalili K, White MK. Lublin F, Ferrante P, Berger JR. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology. 2007; 68;985-990.
3. Ferrante P, Omodeo-Zorini E. Caldarelli-Stefano R, et al. Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients. Mult Scler. 1998;4:49-54.
4. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008;111:3893-3895.